Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.
Tae-Hwan KimMitsumasa KishimotoJames Cheng-Chung WeiHaeyoun JeongAkiyo NozakiShigeto Kobayashinull nullPublished in: Rheumatology (Oxford, England) (2022)
ClinicalTrials.gov, https://clinicaltrials.gov, NCT02985983.